Drug Trial Radar · NCT01332695
A Pilot Efficacy and Safety Study of ST101 in Essential Tremor
Last checked: Nov 19, 2026Latest source record: Jan 6, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Apr 2011
Primary completion
Dec 2011
Study completion Dec 2011
Sponsor
- Lead sponsor
- Sonexa Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 11, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will look at the ability of ST101 to treat symptoms in subjects with Essential Tremor. This study will also examine the safety and tolerability of the drug. This study is evaluating one dose level of ST101 versus placebo in a cross-over fashion. This means that all patients will receive both ST101 and placebo, but they will receive it in a random (by chance) order.
Conditions
- Essential Tremor
Interventions
ST101Drug
tablets for oral administration
PlaceboDrug
placebo to match
Primary outcomes
What the sponsor says the trial is designed to measure.
- Washington Heights-Inwood Genetic Study of Essential Tremor (WHIGET) Rating ScaleTime frame: Baseline, Week 3, Week 5, Week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Los Angeles, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.